Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Diagnosis of mastocytosis: emerging iceberg?

Julien Rossignol, Michel Arock

Blood (2024) 144 (4): 350–352.

https://doi.org/10.1182/blood.2024024943

Published: 2024

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Mael Heiblig, Clement Gourguechon, Philippe Guilpain, Cristina Bulai Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Gandhi Laurent Damaj, Thomas Ballul, Céline Greco, Laura Polivka, Laurent Frenzel, Cecile Meni, Hassiba Bouktit, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Ludovic Lhermitte, Marie Temple, Olivier Kosmider, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frédérique Retornaz, Quentin Cabrera, Patricia Zunic, Marie-Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean-Francois Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose-Miguel Torregrosa-Diaz, Angele Soria, Michel Arock, Christine Bodemer, Olivier Lortholary, Olivier Hermine, Julien Rossignol

Blood (2023) 142 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2023-185890

Published: 2023

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Richard Lemal, MD, Guillemette Fouquet, Louis Terriou, MD, Mélanie Vaes, MD, Cristina Livideanu, MD, Laurent Frenzel, MD PhD, Stéphane Barete, Danielle Canioni, MD, Ludovic Lhermitte, MD PhD, Jacques-Olivier Bay, MD PhD, Julien Rossignol, MD PhD, Michel Arock, Olivier Lortholary, Olivier Hermine, MD PhD

Blood (2018) 132 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2018-99-114739

Published: 2018

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Blood (2018) 132 (18): 1936–1950.

https://doi.org/10.1182/blood-2018-02-833582

Published: 2018

Includes: Supplemental data

Journal Articles

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Niklas Mueller, MD, Daniel Wicklein, PhD, Gregor Eisenwort, MD PhD, Juliana Schwaab, MD, Mohamad Jawhar, MD, Alexandra Boehm, MD, Harald Herrmann, MD, Gabriele Stefanzl, Gregor Hoermann, Wolfgang R. Sperr, MD, Michel Arock, PharmD,PhD, Andreas Reiter, MD, Udo Schumacher, MD, Peter Valent, MD

Blood (2016) 128 (22): 1955.

https://doi.org/10.1182/blood.V128.22.1955.1955

Published: 2016

Journal Articles

Mast cell differentiation: still open questions?

Michel Arock

Blood (2016) 127 (4): 373–374.

https://doi.org/10.1182/blood-2015-12-686592

Published: 2016

Journal Articles

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Blood (2014) 124 (1): 111–120.

https://doi.org/10.1182/blood-2013-10-534685

Published: 2014

Includes: Supplemental data

Journal Articles

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Sabine Cerny-Reiterer, D.V.M, Anja Rabenhorst, Msc, Ph.D., Gabriele Stefanzl, Msc, Susanne Herndlhofer, Katharina Blatt, MSc, Ph.D., Gregor Hoermann, M.D., Ph.D., Leonhard Muellauer, M.D., Sigrid Baumgartner, M.D., Christine Beham-Schmid, M.D., Wolfgang R Sperr, M.D., Werner Linkesch, M.D., Christine Mannhalter, M.D., Michel Arock, PharmD, Ph.D, Karin Hartmann, M.D., Peter Valent

Blood (2013) 122 (21): 3988.

https://doi.org/10.1182/blood.V122.21.3988.3988

Published: 2013

Journal Articles

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Ghaith Wedeh, Emir Hadzijusufovic, DVM, Sabine Cerny-Reiterer, D.V.M, Harald Herrmann, M.D., Katharina Blatt, MSc, Ph.D., Gregor Eisenwort, M.D., Ph.D, Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Leonhard Müllauer, M.D., Christopher R. Vakoc, M.D., Ph.D., James E Bradner, MD, Hans-Peter Horny, MD, Michael Willmann, D.V.M., Johannes Zuber, MD, Michel Arock, PharmD, Ph.D, Peter Valent

Blood (2013) 122 (21): 3747.

https://doi.org/10.1182/blood.V122.21.3747.3747

Published: 2013

Journal Articles

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

Blood (2013) 121 (13): 2393–2401.

https://doi.org/10.1182/blood-2012-09-458521

Published: 2013

Includes: Supplemental data

Journal Articles

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

Peter Valent, Michel Arock, Cem Akin, Wolfgang R. Sperr, Andreas Reiter, Karl Sotlar, Karin Hartmann, Tracy I. George, Knut Brockow, Hanneke C. Kluin-Nelemans, Jason Gotlib, Dean D. Metcalfe, Hans-Peter Horny

Blood (2010) 116 (5): 850–851.

https://doi.org/10.1182/blood-2010-05-285270

Published: 2010

Journal Articles

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells

Blood (2006) 108 (3): 1065–1072.

https://doi.org/10.1182/blood-2005-06-2433

Published: 2006

Journal Articles

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Fanny Lanternier, MD, Annick Cohen-Akenine, PhD, Fabienne Palmerini, PhD, Frederic Feger, MD, Laurent Nasca, PhD, Stephane Barete, MD, David Guez, MD, Philippe Casassus, MD, PhD, Christine Bodemer, MD, PhD, Michel Arock, MD, PhD, Patrice Dubreuil, MD, PhD, Olivier Hermine, MD, PhD, Olivier Lortholary, MD, PhD

Blood (2005) 106 (11): 3091.

https://doi.org/10.1182/blood.V106.11.3091.3091

Published: 2005

Journal Articles

Lack of Detection of FIP1L1-PDGFRA Gene Fusion in a Cohort of Mastocytosis with Eosinophilia.

Stephane Barete, Frederic Feger, Eric Delabesse, Olivier Lortholary, Philippe Casassus, Michel Arock, Fabienne Palmerini, Parice Dubreuil, Christian de Gennes, Camille Frances, Elisabeth A. Macintyre, Olivier Hermine

Blood (2005) 106 (11): 4967.

https://doi.org/10.1182/blood.V106.11.4967.4967

Published: 2005

Journal Articles

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells

Blood (2005) 105 (3): 1256–1264.

https://doi.org/10.1182/blood-2004-06-2416

Published: 2005

Journal Articles

Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.

Olivier Lortholary, MD, PhD, Jacques Vargaftig, MD, Frederic Feger, PhD, Fabienne Palmerini, Richard Delarue, MD, Valerie Ferriole, Jean Marie Launay, MD, Isabelle Bonte, MD, Stephane Barete, MD, Christine Bodemer, MD, Sylvie Freytag, MD, Philippe Casassus, MD, Michel Arock, PhD, Patrice Dubreuil, PhD, Olivier Hermine, MD, PhD.

Blood (2004) 104 (11): 661.

https://doi.org/10.1182/blood.V104.11.661.661

Published: 2004

NARROW

Diagnosis of mastocytosis: emerging iceberg?

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Omalizumab: Efficacy and Safety in Mast Cell Disorders

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Mast cell differentiation: still open questions?

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Lack of Detection of FIP1L1-PDGFRA Gene Fusion in a Cohort of Mastocytosis with Eosinophilia.

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells

Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only